Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | UTHR |
---|---|---|
09:32 ET | 2805 | 354.04 |
09:34 ET | 400 | 352.855 |
09:36 ET | 888 | 350.82 |
09:38 ET | 1056 | 350.585 |
09:41 ET | 1909 | 348.15 |
09:43 ET | 1002 | 347.625 |
09:45 ET | 1414 | 345.87 |
09:48 ET | 349 | 347.3354 |
09:50 ET | 1331 | 345 |
09:52 ET | 1624 | 345.06 |
09:54 ET | 400 | 345.2 |
09:56 ET | 4361 | 345.03 |
09:59 ET | 300 | 345.305 |
10:01 ET | 600 | 345.0675 |
10:03 ET | 583 | 346.015 |
10:15 ET | 200 | 347.29 |
10:17 ET | 130 | 346.3301 |
10:19 ET | 100 | 346.915 |
10:21 ET | 100 | 347.5 |
10:24 ET | 100 | 347.37 |
10:28 ET | 100 | 347.68 |
10:30 ET | 1175 | 348.505 |
10:35 ET | 100 | 348.9793 |
10:37 ET | 104 | 348.856 |
10:39 ET | 281 | 348.325 |
10:44 ET | 100 | 348.385 |
10:48 ET | 100 | 348.6253 |
10:50 ET | 1350 | 347.81 |
10:51 ET | 100 | 348.59 |
10:55 ET | 100 | 348.86 |
11:00 ET | 402 | 348.28 |
11:09 ET | 100 | 348.99 |
11:11 ET | 26003 | 348.26 |
11:13 ET | 100 | 348.185 |
11:15 ET | 200 | 348.265 |
11:20 ET | 200 | 348.46 |
11:22 ET | 300 | 349.4 |
11:24 ET | 100 | 349.25 |
11:31 ET | 230 | 348.995 |
11:33 ET | 100 | 349.005 |
11:36 ET | 250 | 348.8487 |
11:40 ET | 575 | 348.64 |
11:42 ET | 100 | 348.86 |
11:44 ET | 100 | 348.96 |
11:47 ET | 200 | 348.945 |
11:49 ET | 200 | 348.935 |
11:51 ET | 200 | 348.92 |
11:56 ET | 100 | 349.39 |
12:02 ET | 100 | 349.71 |
12:05 ET | 800 | 349.22 |
12:09 ET | 500 | 349.94 |
12:12 ET | 100 | 349.51 |
12:16 ET | 100 | 350.11 |
12:18 ET | 1600 | 349.785 |
12:20 ET | 100 | 349.785 |
12:30 ET | 475 | 350.18 |
12:38 ET | 501 | 349.19 |
12:39 ET | 600 | 349.095 |
12:41 ET | 1167 | 349.3 |
12:45 ET | 200 | 349.02 |
12:54 ET | 174 | 350.05 |
12:56 ET | 700 | 349.565 |
12:57 ET | 100 | 349.01 |
12:59 ET | 700 | 348.93 |
01:03 ET | 100 | 349 |
01:06 ET | 500 | 348.85 |
01:10 ET | 100 | 348.89 |
01:15 ET | 100 | 349.105 |
01:19 ET | 100 | 349.49 |
01:21 ET | 100 | 349.58 |
01:26 ET | 100 | 349.47 |
01:28 ET | 100 | 349.345 |
01:35 ET | 100 | 349.5 |
01:37 ET | 200 | 350 |
01:46 ET | 100 | 350.4 |
01:48 ET | 700 | 350.82 |
01:50 ET | 200 | 350.79 |
01:53 ET | 300 | 351.34 |
02:00 ET | 286 | 351.72 |
02:02 ET | 200 | 352.04 |
02:06 ET | 612 | 352.0162 |
02:08 ET | 400 | 351.475 |
02:09 ET | 500 | 351.23 |
02:15 ET | 100 | 351.52 |
02:20 ET | 100 | 351.47 |
02:22 ET | 400 | 351.055 |
02:29 ET | 700 | 350.635 |
02:31 ET | 200 | 350.67 |
02:36 ET | 300 | 350.73 |
02:40 ET | 400 | 350.705 |
02:42 ET | 300 | 351.25 |
02:51 ET | 100 | 351.17 |
02:56 ET | 100 | 351.35 |
03:02 ET | 200 | 351.28 |
03:03 ET | 500 | 351.11 |
03:05 ET | 300 | 351.08 |
03:09 ET | 1100 | 350.82 |
03:12 ET | 100 | 350.965 |
03:14 ET | 300 | 350.945 |
03:21 ET | 200 | 351.25 |
03:23 ET | 100 | 351.255 |
03:25 ET | 100 | 351.18 |
03:27 ET | 1300 | 351.16 |
03:30 ET | 200 | 351.17 |
03:32 ET | 790 | 351.11 |
03:36 ET | 526 | 350.74 |
03:38 ET | 1400 | 351.26 |
03:41 ET | 315 | 351.265 |
03:43 ET | 1284 | 350.94 |
03:50 ET | 313 | 350.99 |
03:52 ET | 1637 | 351.54 |
03:54 ET | 1218 | 351.74 |
03:56 ET | 1915 | 352.56 |
03:57 ET | 4834 | 352.34 |
03:59 ET | 35634 | 352.47 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
United Therapeutics Corp | 15.9B | 16.2x | +8.22% |
Biomarin Pharmaceutical Inc | 13.3B | 52.5x | --- |
Exact Sciences Corp | 12.6B | -69.6x | --- |
Neurocrine Biosciences Inc | 11.5B | 34.4x | +62.04% |
Qiagen NV | 10.1B | 139.4x | +12.66% |
Medpace Holdings Inc | 10.3B | 31.7x | +35.10% |
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.9B |
---|---|
Revenue (TTM) | $2.6B |
Shares Outstanding | 44.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.57 |
EPS | $21.75 |
Book Value | $127.23 |
P/E Ratio | 16.2x |
Price/Sales (TTM) | 6.1 |
Price/Cash Flow (TTM) | 14.1x |
Operating Margin | 48.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.